Show simple item record

dc.contributor.authorChorlton, Jen_US
dc.contributor.authorHollowood, Zen_US
dc.contributor.authorDyer, Cen_US
dc.contributor.authorLockhart, Den_US
dc.contributor.authorBoekman, Pen_US
dc.contributor.authorMcCafferty, Ken_US
dc.contributor.authorCoffey, Pen_US
dc.contributor.authorMarelli-Berg, Fen_US
dc.contributor.authorMartin, Jen_US
dc.date.accessioned2023-12-06T11:52:15Z
dc.date.available2022-07-18en_US
dc.date.issued2022en_US
dc.identifier.otherARTN 101604
dc.identifier.otherARTN 101604
dc.identifier.otherARTN 101604en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/92669
dc.relation.ispartofECLINICALMEDICINEen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectCOVID-19en_US
dc.subjectSARs-COV-2en_US
dc.subjectAZD1656en_US
dc.subjectGlucokinase activatoren_US
dc.subjectDiabetesen_US
dc.subjectRegulatory T cellsen_US
dc.subjectTregsen_US
dc.subjectImmuneen_US
dc.subjectClinical trialen_US
dc.subjectARCADIAen_US
dc.subjectCytokineen_US
dc.subjectImmunophenotypingen_US
dc.titleA randomised, double-blind, placebo-controlled, multicentre clinical trial of AZD1656 in diabetic patients hospitalised with COVID-19: The ARCADIA Trial- implications for therapeutic immune modulationen_US
dc.typeArticle
dc.identifier.doi10.1016/j.eclinm.2022.101604en_US
pubs.author-urlhttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000864521100007&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6aen_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume51en_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 3.0 United States
Except where otherwise noted, this item's license is described as Attribution 3.0 United States